In this study, mutational profiling was performed on paired samples from patients with relapsed or refractory CLL who were treated with covalent BTKis (ibrutinib or acalabrutinib) in the ELEVATE-RR study. Here we can see the distribution of BTK and B-cell receptor pathway mutations that developed during treatment with ibrutinib or acalabrutinib.